Entering text into the input field will update the search result below

Pfizer, OPKO receive somatrogon Complete Response Letter for growth hormone deficiency

Jan. 21, 2022 5:06 PM ETPfizer Inc. (PFE) Stock, OPK StockBy: Jonathan Block, SA News Editor11 Comments

FDA headquarters in Washington DC.

JHVEPhoto/iStock Editorial via Getty Images

  • The FDA has issued Pfizer (NYSE:PFE) and OPKO Health (NASDAQ:OPK) a Complete Response Letter for their Biologics License Application ("BLA") for somatrogon.
  • OPKO shares are down 9% in after-hours trading.
  • The candidate is a once-weekly, long-acting recombinant

Recommended For You

Related Stocks

SymbolLast Price% Chg
PFE
--
OPK
--